Antibiotic Treatment for Group B Streptococcus UTI

Primary Recommendation

• The Centers for Disease Control and Prevention recommends penicillin or ampicillin as the first-line treatment for Group B Streptococcus urinary tract infections in non-allergic patients, as all GBS isolates worldwide remain 100% susceptible to penicillin 1

Treatment Algorithm Based on Penicillin Allergy Status

• For non-penicillin allergic patients, the American College of Obstetricians and Gynecologists recommends penicillin G 5 million units IV initially, then 2.5-3.0 million units IV every 4 hours as the preferred regimen 2
• The Infectious Diseases Society of America recommends ampicillin 2g IV initially, then 1g IV every 4 hours as an acceptable alternative for non-penicillin allergic patients 3, 2
• For patients with non-severe penicillin allergy, the Centers for Disease Control and Prevention recommends cefazolin 2g IV initially, then 1g IV every 8 hours 2, 4, 1

Critical Laboratory Considerations

• The Centers for Disease Control and Prevention recommends always obtaining clindamycin and erythromycin susceptibility testing for penicillin-allergic patients at high risk for anaphylaxis 2, 4, 1
• The American Society for Microbiology recommends performing D-zone testing on isolates that are erythromycin-resistant but clindamycin-susceptible to detect inducible clindamycin resistance 4, 1

Resistance Patterns and Clinical Pitfalls

• The Centers for Disease Control and Prevention reports that clindamycin resistance ranges from 3-15% among invasive GBS isolates 1
• The American College of Obstetricians and Gynecologists notes that no confirmed resistance to penicillin or ampicillin has been observed worldwide 1

Special Considerations for Pregnancy

• The American College of Obstetricians and Gynecologists recommends that in pregnant women with GBS bacteriuria (≥10⁴ CFU/ml), treatment is mandatory regardless of symptoms 2, 4
• The Centers for Disease Control and Prevention recommends that laboratories should report GBS in urine when present at concentrations ≥10⁴ CFU/ml 4

Treatment of Severe Penicillin Allergy

• The Infectious Diseases Society of America recommends vancomycin 1g IV every 12 hours if the isolate is resistant to clindamycin or erythromycin, demonstrates inducible clindamycin resistance, or if susceptibility is unknown 2, 1
• The American College of Obstetricians and Gynecologists recommends clindamycin 900 mg IV every 8 hours if the isolate is susceptible to both clindamycin and erythromycin 2, 1

Guideline Recommendations for Management of Group B Streptococcus Urinary Tract Infection

Allergy Assessment and Management

• High‑risk penicillin allergy is defined as a history of anaphylaxis, angioedema, respiratory distress, or urticaria after exposure to penicillin or a cephalosporin. [​5, 6]
• Approximately 10 % of patients with penicillin allergy exhibit cross‑reactivity to cephalosporins, but cefazolin remains safe for individuals without high‑risk allergic symptoms. [​5]
• Clindamycin resistance among GBS isolates ranges from 3 % to 15 %; therefore, susceptibility testing for clindamycin and erythromycin must be obtained promptly in high‑risk allergic patients. [​5]
• When an isolate is erythromycin‑resistant but clindamycin‑susceptible, D‑zone testing is required to detect inducible clindamycin resistance. [​5, 6]
• For patients with high‑risk penicillin allergy, immediate susceptibility testing should be ordered to guide selection of clindamycin (if susceptible) or vancomycin (if resistant/unknown). [​5, 6]

Pregnancy‑Specific Management

• Any detection of GBS in urine during pregnancy at a concentration ≥ 10⁴ CFU/mL mandates immediate antimicrobial treatment and mandatory intrapartum IV antibiotic prophylaxis during labor, irrespective of prior UTI therapy. [​6]

Laboratory Reporting Requirements

• Clinical laboratories must report GBS in urine cultures when the organism is present at ≥ 10⁴ CFU/mL, either in pure culture or mixed with a second microorganism. [​5, 6]

Prophylaxis Pitfalls

• Oral antibiotics administered before labor to eradicate GBS colonization in pregnant women are ineffective and should never be used; intrapartum IV prophylaxis is required. [​7]

Management of Group B Streptococcus Urinary Tract Infection in Patients Allergic to Penicillins and Cephalosporins

Diagnostic Testing

• Order immediate clindamycin and erythromycin susceptibility testing when GBS is isolated from a patient with a penicillin allergy; clindamycin resistance is reported in 3 %–15 % of isolates, so therapy must be guided by confirmed susceptibility. (CDC MMWR Recommendations) 8
• Perform D‑zone testing on any isolate that is erythromycin‑resistant but appears clindamycin‑susceptible to uncover inducible clindamycin resistance, which would render clindamycin therapy ineffective despite standard susceptibility results. (CDC MMWR Recommendations) 8

Allergy Assessment

• Classify a penicillin allergy as “high‑risk” when the patient has a history of anaphylaxis, angioedema, respiratory distress, or urticaria after penicillin or cephalosporin exposure; this classification determines whether β‑lactam alternatives can be considered. (CDC MMWR Recommendations) 8

Alternative Antimicrobial Options

• Aztreonam may be used in patients with confirmed penicillin and cephalosporin allergy because it exhibits negligible immunologic cross‑reactivity with other β‑lactams. (Clinical Microbiology and Infection) 9
• Carbapenems (e.g., ertapenem) are also safe options for patients with confirmed penicillin allergy, as cross‑reactivity with these agents is minimal. (Clinical Microbiology and Infection) 9

Management of Group B Streptococcus Urinary Tract Infections in Penicillin‑Allergic Patients

Allergy Risk Stratification

• High‑risk penicillin allergy is defined as a documented history of anaphylaxis, angioedema, respiratory distress, or urticaria after exposure to penicillin or a cephalosporin. This definition is endorsed by the CDC MMWR Recommendations and Reports. 10

Laboratory Testing Prior to Therapy

• Immediate susceptibility testing for clindamycin and erythromycin should be performed on the GBS isolate before initiating therapy in patients with high‑risk penicillin allergy. Recommendation from the CDC MMWR Recommendations and Reports. 10
• D‑zone testing is required when the isolate is erythromycin‑resistant but appears clindamycin‑susceptible, to detect inducible clindamycin resistance that would render clindamycin ineffective despite standard susceptibility results. Guidance from the CDC MMWR Recommendations and Reports. 10